CN113387884A - Preparation method of montelukast sodium impurity H - Google Patents
Preparation method of montelukast sodium impurity H Download PDFInfo
- Publication number
- CN113387884A CN113387884A CN202110757751.8A CN202110757751A CN113387884A CN 113387884 A CN113387884 A CN 113387884A CN 202110757751 A CN202110757751 A CN 202110757751A CN 113387884 A CN113387884 A CN 113387884A
- Authority
- CN
- China
- Prior art keywords
- montelukast sodium
- impurity
- sodium impurity
- benzoate
- hydroxypropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FVMXWBDOMBDOJN-JLBZDQGGSA-N 2-[1-[[(1r)-1-[3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-(2-methoxycarbonylphenyl)propyl]sulfanylmethyl]cyclopropyl]acetic acid Chemical compound COC(=O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 FVMXWBDOMBDOJN-JLBZDQGGSA-N 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 238000006243 chemical reaction Methods 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 14
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims abstract description 13
- VFAXPOVKNPTBTM-UHFFFAOYSA-N 2-[1-(sulfanylmethyl)cyclopropyl]acetic acid Chemical compound OC(=O)CC1(CS)CC1 VFAXPOVKNPTBTM-UHFFFAOYSA-N 0.000 claims abstract description 9
- 150000001263 acyl chlorides Chemical class 0.000 claims abstract description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 24
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 16
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 239000012074 organic phase Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 claims description 6
- 239000007810 chemical reaction solvent Substances 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- 238000000967 suction filtration Methods 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 claims description 3
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 claims description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- OUCSEDFVYPBLLF-KAYWLYCHSA-N 5-(4-fluorophenyl)-1-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-n,4-diphenyl-2-propan-2-ylpyrrole-3-carboxamide Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H]2OC(=O)C[C@H](O)C2)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 OUCSEDFVYPBLLF-KAYWLYCHSA-N 0.000 abstract description 14
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 238000000746 purification Methods 0.000 abstract description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 abstract 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 2
- 229940126062 Compound A Drugs 0.000 abstract 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 1
- 238000006555 catalytic reaction Methods 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 description 42
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 40
- 238000001228 spectrum Methods 0.000 description 21
- 229960001951 montelukast sodium Drugs 0.000 description 10
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 description 10
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 239000012535 impurity Substances 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 238000002072 distortionless enhancement with polarization transfer spectrum Methods 0.000 description 5
- FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 5
- SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical compound C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- OKTJSMMVPCPJKN-IGMARMGPSA-N Carbon-12 Chemical group [12C] OKTJSMMVPCPJKN-IGMARMGPSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 102000003835 leukotriene receptors Human genes 0.000 description 1
- 108090000146 leukotriene receptors Proteins 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Quinoline Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a method for preparing montelukast sodium impurity H. According to the invention, methyl 2- (2- (3 (S) - (2- (7-chloro-2-quinolyl) -vinyl) phenyl) -3-hydroxypropyl) benzoate (compound A) reacts with an acyl chloride reagent under the catalysis of triethylamine to generate a mesylate derivative, and finally the mesylate derivative reacts with 1-mercaptomethylcyclopropylacetic acid (compound B) to generate montelukast sodium impurity H. According to the method, the intermediate of the impurity H is not required to be dried, the intermediate can be directly put into the next reaction, column purification is not required, the preparation period is effectively shortened, the working efficiency is improved, and the purity of the impurity H is more than 98.0%.
Description
Technical Field
The application belongs to the field of medicine synthesis, and particularly relates to a preparation method of montelukast sodium impurity H.
Background
Montelukast sodium (known as cistronic) is a potent leukotriene receptor antagonist developed by merck corporation, and can selectively bind to leukotriene receptors in the respiratory tract, block the action of allergic mediators, ameliorate respiratory inflammation, and promote airway patency. The first time in finland and mexico in 1998, in uk and in the united states in months 4 and 10 in the same year, respectively, and in 2002 to land in the chinese market. According to the recommendation of 'the guideline for prevention and treatment of bronchial asthma' 2008 edition in China, the leukotriene regulator is the only long-term drug control agent which can be used independently except inhalation hormone, and can be used as a drug for replacement therapy of mild asthma and a drug for combined therapy of moderate and severe asthma.
At present, no literature report exists on the preparation of the montelukast sodium impurity H. The quality standard of montelukast sodium in the united states pharmacopeia (USP-NF 2021), especially the relevant material items, are more strictly defined, and the limit of a single impurity is not more than 0.10% (the limit of the impurity H of montelukast sodium is not more than 0.1%) except for 5 impurities of the structural formula listed in the pharmacopeia. In recent years, with the progress of the evaluation of the consistency of pharmaceuticals, the quality of pharmaceuticals, particularly the study of impurities, has become more important.
Disclosure of Invention
The invention aims to provide a method for synthesizing an impurity H of montelukast sodium. The method is simple to operate, has a short reaction period, and provides a qualified reference substance for the quality control of the montelukast sodium raw material medicine.
In order to achieve the purpose, the technical scheme adopted by the application is as follows:
a preparation method of montelukast sodium impurity H comprises the following steps:
the preparation method of the montelukast sodium impurity H comprises the following steps:
(1) taking dichloromethane as a reaction solvent, adding methyl 2- (2- (3 (S) - (2- (7-chloro-2-quinolyl) -vinyl) phenyl) -3-hydroxypropyl) benzoate, adding N, N-diisopropylethylamine, cooling to 0-5 ℃, dropwise adding an acyl chloride reagent, keeping the temperature at-15 ℃ after dropwise adding, and reacting for 60-120 min;
(2) after the reaction in the step (1) is finished, adding 30% sodium methoxide solution (5 mol/L) into the step (1) under the protection of nitrogen, cooling to-5-0 ℃, adding 1-mercaptomethylcyclopropyl acetic acid, keeping the temperature at-5-0 ℃, stirring for reacting for 6 hours, detecting by TLC, and completely reacting;
(3) and (3) adding purified water and ethyl acetate into the reaction system treated in the step (2), dropwise adding 0.5mol/L tartaric acid solution, stirring for 1 hour when the pH value is 5-6 after the dropwise adding is finished, standing, separating, concentrating the organic phase, dropwise adding the organic phase into n-heptane, growing crystals for 30min, performing suction filtration, and drying to obtain the montelukast sodium impurity H.
In the step (1), methyl 2- (2- (3 (S) - (2- (7-chloro-2-quinolinyl) -vinyl) phenyl) -3-hydroxypropyl) benzoate: dichloromethane: n, N-diisopropylethylamine: the mass ratio of the acyl chloride reagent is as follows: 1: 10-15: 0.5-1.0: 0.55-0.75.
The acyl chloride reagent is selected from any one of methanesulfonyl chloride, p-toluenesulfonyl chloride, benzenesulfonyl chloride or sulfonyl chloride.
In the step (2), methyl 2- (2- (3 (S) - (2- (7-chloro-2-quinolinyl) -vinyl) phenyl) -3-hydroxypropyl) benzoate: 30% sodium methoxide: the mass ratio of the 1-mercaptomethylcyclopropyl acetic acid is as follows: 1: 2.35-3.50: 0.35 to 0.55.
In the step (3), methyl 2- (2- (3 (S) - (2- (7-chloro-2-quinolinyl) -vinyl) phenyl) -3-hydroxypropyl) benzoate: ethyl acetate: water: the mass ratio of the n-heptane is as follows: 1: 5.5-7.5: 15.0-25.0: 10.0-15.0.
The invention has the beneficial effects that: provides a method for synthesizing the montelukast sodium impurity H. The method is simple to operate, has a short reaction period, and provides a qualified reference substance for the quality control of the montelukast sodium raw material medicine. According to the method, the intermediate of the impurity H is not required to be dried, the intermediate can be directly put into the next reaction, column purification is not required, the preparation period is effectively shortened, the working efficiency is improved, and the purity of the impurity H is more than 98.0%.
Detailed Description
The following examples are given solely for the purpose of illustration and are not intended to limit the scope of the invention
Example 1
Using methylene chloride as a reaction solvent, 50g of methyl 2- (2- (3 (S) - (2- (7-chloro-2-quinolyl) -vinyl) phenyl) -3-hydroxypropyl) benzoate (109 mmol) and N, N-diisopropylethylamine (28.5 mL) were added to 550mL of methylene chloride, cooled to 0 ℃ and methanesulfonyl chloride (16.3 g, 142 mmol) was slowly added dropwise, and the reaction was incubated for 90min after completion of the dropwise addition. Under the protection of nitrogen, 37g of 30% sodium methoxide (5 mol/L) is added, the temperature is reduced to minus 5 ℃, 15.5g of 1-mercaptomethylcyclopropyl acetic acid (111 mmol) is added, the temperature is kept at minus 5 ℃, and the mixture is stirred and reacted for about 6 hours. And (5) detecting by TLC, and completing the reaction. Adding purified water and ethyl acetate, dropwise adding 0.5mol/L tartaric acid solution, stirring for 1 hour when the pH value is between 5 and 6 after the dropwise adding is finished, and finishing the reaction. Standing, separating, concentrating an organic phase, dropwise adding the organic phase into 600ml of n-heptane, growing crystals for about 30min, performing suction filtration, and drying to obtain an impurity H3.92 g of montelukast sodium; the purity is 98.6%.
Example 2
Using methylene chloride as a reaction solvent, 20g of methyl 2- (2- (3 (S) - (2- (7-chloro-2-quinolyl) -vinyl) phenyl) -3-hydroxypropyl) benzoate (43.6 mmol) and N, N-diisopropylethylamine (11.4 mL) were added to 200mL of methylene chloride, the mixture was cooled to 0 ℃ and p-toluenesulfonyl chloride (10.83 g, 56.8 mmol) was slowly added dropwise, and the reaction was allowed to proceed for 60min after completion of dropwise addition. Under the protection of nitrogen, 14.8g of 30% sodium methoxide was added, the temperature was reduced to-5 ℃, 6.2g of 1-mercaptomethylcyclopropylacetic acid (44.4 mmol) was added, the temperature was maintained at-5 ℃, and the reaction was stirred for about 6 hours. And (5) detecting by TLC, and completing the reaction. Adding purified water and ethyl acetate, dropwise adding 0.5mol/L tartaric acid solution, stirring for 1 hour when the pH value is between 5 and 6 after the dropwise adding is finished, and finishing the reaction. Standing, separating, concentrating an organic phase, dropwise adding the organic phase into 240ml of n-heptane, growing crystals for about 30min, performing suction filtration, and drying to obtain a montelukast sodium impurity H1.32 g; the purity is 98.3%.
Example 3
Methylene chloride was used as a reaction solvent, 10g of methyl 2- (2- (3 (S) - (2- (7-chloro-2-quinolyl) -vinyl) phenyl) -3-hydroxypropyl) benzoate (26.8 mmol) and N, N-diisopropylethylamine (5.7 mL) were added to 110mL of methylene chloride, the mixture was cooled to 0 ℃ and benzenesulfonyl chloride (5.41 g, 28.4 mmol) was slowly added dropwise, and the mixture was reacted for 120min after dropwise addition. Under the protection of nitrogen, 7.4g of 30% sodium methoxide was added, the temperature was reduced to-5 ℃, 3.1g of 1-mercaptomethylcyclopropylacetic acid (22.2 mmol) was added, the temperature was maintained at-5 ℃, and the reaction was stirred for about 6 hours. And (5) detecting by TLC, and completing the reaction. Adding purified water and ethyl acetate, dropwise adding 0.5mol/L tartaric acid solution, stirring for 1 hour when the pH value is between 5 and 6 after the dropwise adding is finished, and finishing the reaction. Standing, separating, concentrating the organic phase, dripping the organic phase into 120ml of n-heptane, growing crystals for about 30min, performing suction filtration, and drying to obtain 0.70g of montelukast sodium impurity H; the purity of the product is 98.1 percent,
example 4
Using methylene chloride as a reaction solvent, 25g of methyl 2- (2- (3 (S) - (2- (7-chloro-2-quinolyl) -vinyl) phenyl) -3-hydroxypropyl) benzoate (54.5 mmol) and N, N-diisopropylethylamine (14.2 mL) were added to 250mL of methylene chloride, cooled to 0 ℃ and sulfuryl chloride (8.54 g, 71 mmol) was slowly added dropwise, and after completion of the addition, the reaction was incubated for 60 min. Under the protection of nitrogen, 18.5g of 30% sodium methoxide was added, the temperature was reduced to-5 ℃, 7.75g of 1-mercaptomethylcyclopropyl acetic acid (55.5 mmol) was added, the temperature was maintained at-5 ℃, and the reaction was stirred for about 6 hours. And (5) detecting by TLC, and completing the reaction. Adding purified water and ethyl acetate, dropwise adding 0.5mol/L tartaric acid solution, stirring for 1 hour when the pH value is between 5 and 6 after the dropwise adding is finished, and finishing the reaction. Standing, separating, concentrating an organic phase, dropwise adding the organic phase into 300ml of n-heptane, growing crystals for about 30min, performing suction filtration, and drying to obtain a montelukast sodium impurity H1.89 g; the purity is 98.6%.
The nuclear magnetic hydrogen spectrum and the nuclear magnetic carbon spectrum are respectively utilized to characterize the structure of the target compound, and the results are as follows:
TABLE 1 impurities H in CDCl3In (1)1H-NMR data
The nmr carbon spectrum data was resolved as follows:
impurity H has 34 carbons in structure, while the 13C spectrum of this product shows 34 carbon peaks, which is consistent with impurity H structure. From the DEPT spectrum and the HMQC spectrum, the 13C spectrum of the impurity H sample can be resolved as follows:
1. the DEPT spectrum shows that the 13C spectrum of the product contains 1 group of primary carbon peaks, which are consistent with the molecular structure of the impurity H. Wherein the primary carbon peak at δ 51.96, associated with δ 3.82 hydrogen 28 in the HMQC spectrum, is assigned as the methyl group at position 28.
2. The DEPT spectrum shows that the 13C spectrum of the product contains 6 groups of secondary carbon peaks, and the structure of the secondary carbon peaks is consistent with that of the impurity H. Wherein the secondary carbon peak of delta 40.08 is related to delta 2.37 and 2.57 hydrogen 30 in the HMQC spectrum and is assigned to 30-position methylene carbon.
3. The secondary carbon peak at δ 38.78, associated with δ 2.47 hydrogen 30a, δ 2.59 hydrogen 30b in the HMQC spectrum, is assigned to the 30-methylene carbon.
4. The secondary carbon peak at δ 38.67, associated with δ 2.21-2.13 hydrogens 20 in the HMQC spectrum, is assigned a methylene carbon at position 20.
5. The secondary carbon peak at δ 32.83, associated with δ 2.92 hydrogens 19a, δ 3.09 hydrogens 19b in the HMQC spectrum, is assigned a methylene carbon at position 19.
6. The secondary carbon peak at δ 12.58, associated with δ 0.51 hydrogen 32 in the HMQC spectrum, is assigned a methylene carbon at position 32.
7. The secondary carbon peak at δ 12.40, associated with δ 0.41 hydrogen 33 in the HMQC spectrum, is assigned the methylene carbon at position 33.
8. The DEPT spectrum shows that the 13C spectrum of the product contains 16 groups of tertiary carbon peaks, and the molecular structure of the product is consistent with that of the impurity H. Wherein the tertiary carbon peak of δ 49.98, associated with δ 3.92 hydrogens 18 in the HMQC spectrum, is assigned to the 18-methine carbon.
9. Because impurity H has low purity, poor low-field peak shape, difficult calculation of coupling constant and difficult recognition of H-H COSY spectrum, the methine hydrogen on 2,3,4,7, 8-position of quinoline ring, 13,14,15,17,22,23,24, 25-position of two benzene rings and 10, 11-position of double bond is difficult to be assigned. Therefore, the carbon spectra corresponding to the above-mentioned methine hydrogens are difficult to be assigned, and all of the carbon spectra corresponding to the above-mentioned methine hydrogens are listed below: 136.48,135.80,132.03,131.04,130.83,129.00,
128. 70,128.37,127.51,127.24,126.71,126.43,126.09,119.13。
25. the DEPT spectrum shows that the 13C spectrum of the product contains 11 groups of quaternary carbon peaks, which are consistent with the molecular structure of the impurity H. Referring to the assignment of the quaternary carbon in the montelukast sodium molecule,
the quaternary carbon peak of delta 176.57 is assigned as quaternary carbon at the 37 carbonyl position; a quaternary carbon peak of δ 168.00 assigned to the carbonyl carbon at position 27; a quaternary carbon peak of δ 156.92, assigned as the quaternary carbon at position 9; a quaternary carbon peak of δ 146.02, assigned as the quaternary carbon at position 5; a quaternary carbon peak of δ 143.41 assigned to quaternary carbon 26; a quaternary carbon peak of δ 143.28, assignable to quaternary carbon 16; a quaternary carbon peak of δ 136.43, assigned as quaternary carbon at position 21; a quaternary carbon peak of δ 135.61, assigned as quaternary carbon 12; a quaternary carbon peak of δ 129.46 assigned to the quaternary carbon at position 6; a quaternary carbon peak of δ 125.62, assigned as quaternary carbon at position 1; delta 16.69, assigned the quaternary carbon at position 31.
Through the analysis of the nuclear magnetic resonance hydrogen spectrogram and the nuclear magnetic resonance carbon spectrogram, the target compound prepared by the method conforms to the structure of the montelukast impurity H.
Claims (6)
1. A preparation method of montelukast sodium impurity H is characterized by comprising the following preparation processes:
2. the method of preparing montelukast sodium impurity H according to claim 1, characterized in that: the method comprises the following steps:
(1) taking dichloromethane as a reaction solvent, adding methyl 2- (2- (3 (S) - (2- (7-chloro-2-quinolyl) -vinyl) phenyl) -3-hydroxypropyl) benzoate, adding N, N-diisopropylethylamine, cooling to 0-5 ℃, dropwise adding an acyl chloride reagent, keeping the temperature at-15 ℃ after dropwise adding, and reacting for 60-120 min;
(2) after the reaction in the step (1) is finished, adding 30% of sodium methoxide in the step (1) under the protection of nitrogen, cooling to-5-0 ℃, adding 1-mercaptomethylcyclopropyl acetic acid, keeping the temperature at-5-0 ℃, stirring for reacting for 6 hours, detecting by TLC, and completely reacting;
(3) and (3) adding purified water and ethyl acetate into the reaction system treated in the step (2), dropwise adding 0.5% tartaric acid solution, stirring for 1 hour when the pH value is 5-6 after the dropwise adding is finished, standing, separating, concentrating the organic phase, dropwise adding the organic phase into n-heptane, growing crystals for 30min, performing suction filtration, and drying to obtain the montelukast sodium impurity H.
3. The method of preparing montelukast sodium impurity H according to claim 2, characterized in that: in step (1), methyl 2- (2- (3 (S) - (2- (7-chloro-2-quinolinyl) -vinyl) phenyl) -3-hydroxypropyl) benzoate: dichloromethane: n, N-diisopropylethylamine: the mass ratio of the acyl chloride reagent is as follows: 1: 10-15: 0.5-1.0: 0.55-0.75.
4. The method of preparing montelukast sodium impurity H according to claim 2, characterized in that: the acyl chloride reagent is selected from any one of methanesulfonyl chloride, p-toluenesulfonyl chloride, benzenesulfonyl chloride or sulfonyl chloride.
5. The method for preparing montelukast sodium impurity H according to claim 1, characterized in that: in step (2), methyl 2- (2- (3 (S) - (2- (7-chloro-2-quinolinyl) -vinyl) phenyl) -3-hydroxypropyl) benzoate: 30% sodium methoxide: the mass ratio of the 1-mercaptomethylcyclopropyl acetic acid is as follows: 1: 2.35-3.50: 0.35 to 0.55.
6. The method for preparing montelukast sodium impurity H according to claim 2, characterized in that: in the step (3), the methyl 2- (2- (3 (S) - (2- (7-chloro-2-quinolyl) -vinyl) phenyl) -3-hydroxypropyl) benzoate: ethyl acetate: water: the mass ratio of the n-heptane is as follows: 1: 5.5-7.5: 15.0-25.0: 10.0-15.0.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110757751.8A CN113387884A (en) | 2021-07-05 | 2021-07-05 | Preparation method of montelukast sodium impurity H |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110757751.8A CN113387884A (en) | 2021-07-05 | 2021-07-05 | Preparation method of montelukast sodium impurity H |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113387884A true CN113387884A (en) | 2021-09-14 |
Family
ID=77625439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110757751.8A Pending CN113387884A (en) | 2021-07-05 | 2021-07-05 | Preparation method of montelukast sodium impurity H |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113387884A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108727386A (en) * | 2018-07-16 | 2018-11-02 | 广州医科大学 | A kind of Pyrazolopyrimidines and its preparation method and application |
| CN110240590A (en) * | 2019-07-16 | 2019-09-17 | 广州新民培林医药科技有限公司 | A kind of pyrimidine quinoline and its preparation method and application |
| CN110407812A (en) * | 2019-07-31 | 2019-11-05 | 武汉工程大学 | A kind of indazole piperidine pyrimidine analog derivative and its preparation method and application |
| CN111848510A (en) * | 2019-04-24 | 2020-10-30 | 山东百诺医药股份有限公司 | Synthesis method of montelukast sodium |
| CN111875548A (en) * | 2020-07-16 | 2020-11-03 | 山东大学 | 5-position aromatic ring substituted diaryl pyrimidine derivative and preparation method and application thereof |
-
2021
- 2021-07-05 CN CN202110757751.8A patent/CN113387884A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108727386A (en) * | 2018-07-16 | 2018-11-02 | 广州医科大学 | A kind of Pyrazolopyrimidines and its preparation method and application |
| CN111848510A (en) * | 2019-04-24 | 2020-10-30 | 山东百诺医药股份有限公司 | Synthesis method of montelukast sodium |
| CN110240590A (en) * | 2019-07-16 | 2019-09-17 | 广州新民培林医药科技有限公司 | A kind of pyrimidine quinoline and its preparation method and application |
| CN110407812A (en) * | 2019-07-31 | 2019-11-05 | 武汉工程大学 | A kind of indazole piperidine pyrimidine analog derivative and its preparation method and application |
| CN111875548A (en) * | 2020-07-16 | 2020-11-03 | 山东大学 | 5-position aromatic ring substituted diaryl pyrimidine derivative and preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| ALIABAD JAVAD MOKHTARI ET AL.: "Development of an efficient and practical approach for the synthesis of montelukast sodium intermediate", 《INTERNATIONAL ELECTRONIC CONFERENCE ON SYNTHETIC ORGANIC CHEMISTRY》 * |
| I.V . SUNILKUMAR ET AL.: "Identification, synthesis and characterization of impurities of Montelukast sodium", 《ASIAN JOURNAL OF CHEMISTRY》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6107519A (en) | Process to produce oxazolidinones | |
| EP3611163A1 (en) | High-purity isothiocyanate compound preparation method for industrial production | |
| CN110078695B (en) | Quercetin derivative and preparation method thereof | |
| EP4183790A1 (en) | Method for large-scale synthesis of tetrodotoxin | |
| CN113387884A (en) | Preparation method of montelukast sodium impurity H | |
| CN110128385B (en) | Quercetin derivative chemically modified by lauroyl chloride and synthetic method thereof | |
| CN102731336B (en) | Linezolid intermediate and synthetic method of linezolid | |
| CN108440626B (en) | Crystal form of cytarabine 5' -O-L-valine ester hydrochloride and preparation method thereof | |
| CN113527338B (en) | Synthesis process of cefozopran hydrochloride | |
| CN110698335A (en) | Synthesis method of terbutaline intermediate | |
| CN111978316B (en) | Synthesis method of ipratropium bromide | |
| CN111362873B (en) | Synthetic method of gatifloxacin metabolite | |
| CN113563285A (en) | Preparation method of novel medicine Vothiocetin for treating major depressive disorder | |
| CN111100042B (en) | Preparation method of 2-methoxy-5-sulfonamide benzoic acid | |
| CN110551064B (en) | Preparation method of isavuconazole sulfate and intermediate thereof | |
| CN109438543B (en) | Preparation method of high-purity fluticasone furoate | |
| CN109678919B (en) | Preparation method of methylprednisolone succinate impurity | |
| CN112110974A (en) | Method for purifying medicinal cholesterol | |
| US20210147344A1 (en) | Amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane salts and methods of making the same | |
| CN114940695B (en) | Androstanol derivative with anti-tumor activity and preparation method and application thereof | |
| CN104725470B (en) | Novel taltirelin crystal form and preparation method and application thereof | |
| CN111606815B (en) | Preparation method of phenylephrine hydrochloride impurity standard | |
| CN108558676B (en) | Preparation method of N, N-dibenzylethylenediamine diacetate | |
| CN114539342A (en) | Preparation method of mixed anhydride and industrial preparation method of tauroursodeoxycholic acid dihydrate | |
| CN105037242A (en) | Diclofenac derivative synthesis process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210914 |
|
| RJ01 | Rejection of invention patent application after publication |